BRIEF — Korean approval for Opdivo in RCC combination

Japanese drugmaker Ono Pharmaceutica has been given the green light to market a combination involving Opdivo (nivolumab) intravenous infusion for previously untreated intermediate and poor risk advanced renal cell carcinoma (RCC) in South Korea.

The combination of Opdivo and Yervoy (ipilimumab) has been approved in this indication by the Ministry of Food and Drug Safety in the Asian country, where there are around 4,500 patients of RCC diagnosed yearly.

The method of administration has also been changed to intravenous infusion over 30 minutes every two weeks, from the current longer duration of 60 minutes each fortnight.